The Europe Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market would witness market growth of 7.9% CAGR during the forecast period (2023-2030).
The rise in the prevalence of sexually transmitted diseases is the main factor fueling the market. Molecular chlamydia trachomatis (CT)/Neisseria gonorrhoeae (NG) diagnostic equipment is expected to expand rapidly over the study period due to increasing emphasis on awareness-raising efforts and government initiatives. Furthermore, businesses competing in the market may benefit greatly from the soaring need for cutting-edge CT/NG testing equipment in the upcoming years.
The healthcare industry will change due to technological developments like point-of-care testing tools and rapid diagnostic techniques, making testing options more accessible and quicker. Furthermore, incorporating molecular diagnostics and genotyping methods will improve the precision and specificity of CT/NG testing, enabling individualized treatment strategies. Additionally, the expanding use of telemedicine and digital health platforms will make remote testing and result distribution possible, guaranteeing comfort and privacy for any individual seeking CT/NG testing services.
The number of sexual health screens (SHSs) that performed diagnostic tests for chlamydia, gonorrhoea, syphilis, or HIV in 2022 was 2,195,909, up 13.4% from 2021 (1,936,455), according to the U.K. government. All ages of people are experiencing an increase in gonorrhoea, although young adults between the ages of 15 to 24 are most affected. Gonorrhoea diagnoses grew to 82,592 diagnoses in 2022, an increase of 50.3% compared to 2021 (54,961), while chlamydia diagnoses (all ages) increased by 24.3% from 160,279 diagnoses in 2021 to 199,233 in 2022. Through the National Chlamydia Screening Programme (NCSP), young women between the ages of 15 to 24 were screened. In 2022, 690,531 chlamydia tests were performed, a 1.2% decrease from 2021 (698,979), and 68,882 chlamydia diagnoses were made, a 21.8% increase from 2021 (56,562). Over the same time, test positivity rose from 8.1% to 10.0%. The market is anticipated to expand in this region due to the rising number of chlamydia diseases.
The Germany market dominated the Europe Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $180 million by 2030. The UK market is exhibiting a CAGR of 7% during (2023 - 2030). Additionally, The France market would experience a CAGR of 8.7% during (2023 - 2030).
Based on Product, the market is segmented into Assays & Kits, and Instruments & Analyzers. Based on End User, the market is segmented into Diagnostic Laboratories, Hospitals & Clinics, and Others. Based on Testing Type, the market is segmented into Lab Tests, and PoC Tests. Based on Technology, the market is segmented into Isothermal Nucleic Acid Amplification Technology, Polymerase Chain Reaction, Immunodiagnostics, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Worldwide Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market is Projected to reach USD 2.8 Billion by 2030, at a CAGR of 8.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Becton, Dickinson and Company, ZeptoMetrix LLC (Antylia Scientific), Danaher Corporation, F. Hoffmann-La Roche Ltd., Hologic, Inc., Thermo Fisher Scientific, Inc., Bayer AG, Qiagen N.V. and Siemens AG.
By Product
By End User
By Testing Type
By Technology
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
